Compare Stocks: AQB, AKTX, ESLA, and MRKR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKTX Akari Therapeutics	$8.72 -1.4%	$9.06	$3.02 ▼ $44.20	$17.21M	1.43	72,735 shs	15,258 shs
AQB AquaBounty Technologies	$0.93 +1.6%	$1.14	$0.77 ▼ $2.82	$4.69M	1.48	87,455 shs	76,145 shs
ESLA Estrella Immunopharma	$0.47 -1.5%	$0.65	$0.43 ▼ $3.15	$20.66M	0.93	43,436 shs	14,485 shs
MRKR Marker Therapeutics	$1.05	$1.21	$0.84 ▼ $2.46	$17.51M	1.53	65,830 shs	100,290 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKTX Akari Therapeutics	-1.36%	-10.66%	-14.09%	-16.23%	-77.76%
AQB AquaBounty Technologies	+1.64%	-2.62%	-21.60%	-10.18%	-63.14%
ESLA Estrella Immunopharma	-1.47%	-2.70%	-32.17%	-52.37%	-65.07%
MRKR Marker Therapeutics	0.00%	-8.70%	-16.00%	-28.57%	+15.56%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKTX Akari Therapeutics	$8.72 -1.4%	$9.06	$3.02 ▼ $44.20	$17.21M	1.43	72,735 shs	15,258 shs
AQB AquaBounty Technologies	$0.93 +1.6%	$1.14	$0.77 ▼ $2.82	$4.69M	1.48	87,455 shs	76,145 shs
ESLA Estrella Immunopharma	$0.47 -1.5%	$0.65	$0.43 ▼ $3.15	$20.66M	0.93	43,436 shs	14,485 shs
MRKR Marker Therapeutics	$1.05	$1.21	$0.84 ▼ $2.46	$17.51M	1.53	65,830 shs	100,290 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKTX Akari Therapeutics	-1.36%	-10.66%	-14.09%	-16.23%	-77.76%
AQB AquaBounty Technologies	+1.64%	-2.62%	-21.60%	-10.18%	-63.14%
ESLA Estrella Immunopharma	-1.47%	-2.70%	-32.17%	-52.37%	-65.07%
MRKR Marker Therapeutics	0.00%	-8.70%	-16.00%	-28.57%	+15.56%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKTX Akari Therapeutics	2.80	Moderate Buy	$32.33	270.80% Upside
AQB AquaBounty Technologies	1.00	Sell	N/A	N/A
ESLA Estrella Immunopharma	2.00	Hold	$8.00	1,609.40% Upside
MRKR Marker Therapeutics	2.25	Hold	$10.00	852.38% Upside

Current Analyst Ratings Breakdown

Latest AQB, AKTX, ESLA, and MRKR Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/24/2026	ESLA Estrella Immunopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/18/2026	MRKR Marker Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/18/2026	AKTX Akari Therapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/14/2026	AQB AquaBounty Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/8/2026	ESLA Estrella Immunopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/4/2026	MRKR Marker Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/28/2026	AQB AquaBounty Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/25/2026	ESLA Estrella Immunopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	MRKR Marker Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	MRKR Marker Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/12/2026	AQB AquaBounty Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	$24.75 per share	N/A
AQB AquaBounty Technologies	N/A	N/A	N/A	N/A	($0.49) per share	N/A
ESLA Estrella Immunopharma	N/A	N/A	N/A	N/A	($0.27) per share	N/A
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A	$1.01 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKTX Akari Therapeutics	-$17.30M	N/A	N/A	N/A	N/A	N/A	-147.45%	-74.70%	12/4/2026 (Estimated)
AQB AquaBounty Technologies	-$18.49M	-$0.82	N/A	N/A	N/A	N/A	-147.07%	-28.73%	11/10/2026 (Estimated)
ESLA Estrella Immunopharma	-$13.06M	-$0.24	N/A	N/A	N/A	N/A	N/A	-328.72%	12/2/2026 (Estimated)
MRKR Marker Therapeutics	-$12.16M	-$0.41	N/A	N/A	N/A	N/A	-56.96%	-47.82%	11/12/2026 (Estimated)

Latest AQB, AKTX, ESLA, and MRKR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	MRKR Marker Therapeutics	-$0.25	-$0.09	+$0.16	-$0.09	$0.68 million	N/A
8/13/2026	Q2 2026	ESLA Estrella Immunopharma	-$0.09	-$0.05	+$0.04	-$0.05	N/A	N/A
8/6/2026	Q2 2026	AQB AquaBounty Technologies	N/A	-$0.26	N/A	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	N/A
AQB AquaBounty Technologies	N/A	N/A	N/A	N/A	N/A
ESLA Estrella Immunopharma	N/A	N/A	N/A	N/A	N/A
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKTX Akari Therapeutics	N/A	0.60	0.60
AQB AquaBounty Technologies	N/A	4.26	4.26
ESLA Estrella Immunopharma	N/A	0.20	0.20
MRKR Marker Therapeutics	N/A	6.03	6.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKTX Akari Therapeutics	5.06%
AQB AquaBounty Technologies	8.92%
ESLA Estrella Immunopharma	0.35%
MRKR Marker Therapeutics	22.39%

Insider Ownership

Company	Insider Ownership
AKTX Akari Therapeutics	32.20%
AQB AquaBounty Technologies	1.02%
ESLA Estrella Immunopharma	5.80%
MRKR Marker Therapeutics	5.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKTX Akari Therapeutics	5	1.95 million	1.32 million	Not Optionable
AQB AquaBounty Technologies	100	5.15 million	5.10 million	No Data
ESLA Estrella Immunopharma	N/A	43.50 million	40.98 million	Not Optionable
MRKR Marker Therapeutics	60	16.67 million	15.72 million	Not Optionable

AQB, AKTX, ESLA, and MRKR Headlines

Recent News About These Companies

Marker Highlights Expanded Manufacturing Support For MT-601

September 22, 2026 | rttnews.com

Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies

September 22, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Marker Therapeutics (MRKR) and CSPC Pharmaceutical Group (OtherCHJTF)

August 22, 2026 | theglobeandmail.com

Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker

June 26, 2026 | zacks.com

5 Small Drug Stocks to Invest in Amid a Biotech Comeback

June 25, 2026 | zacks.com

MARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock?

May 20, 2026 | zacks.com

Marker Therapeutics Sets Date for 2026 Annual Meeting

May 19, 2026 | theglobeandmail.com

Marker Therapeutics (MRKR) price target decreased by 12.83% to 8.02

April 9, 2026 | msn.com

MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates

March 18, 2026 | zacks.com

Marker Therapeutics Reports Encouraging Phase 1 APOLLO Data and Corporate Developments in Immuno-Oncology

March 18, 2026 | quiverquant.comQ

Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

March 18, 2026 | globenewswire.com

Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 18, 2026 | globenewswire.com

Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology

January 26, 2026 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Marker Therapeutics (MRKR), Pasithea Therapeutics Corp (KTTA) and TransMedics Group (TMDX)

January 22, 2026 | theglobeandmail.com

MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know

January 21, 2026 | zacks.com

Marker Therapeutics, Inc. Common Stock (MRKR)

January 9, 2026 | nasdaq.com

MARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy?

January 7, 2026 | zacks.com

5 Small Drug Stocks to Buy as Industry Recovery Picks Up

January 7, 2026 | zacks.com

Marker Therapeutics announces publication on MAR-T cells in pancreatic cancer

January 5, 2026 | msn.com

Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer

January 5, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AQB, AKTX, ESLA, and MRKR Company Descriptions

Akari Therapeutics NASDAQ:AKTX

$8.72 -0.12 (-1.36%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$8.76 +0.04 (+0.46%)

As of 10/2/2026 07:30 PM Eastern

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

AquaBounty Technologies NASDAQ:AQB

$0.93 +0.01 (+1.64%)

As of 10/2/2026 03:59 PM Eastern

AquaBounty Technologies, Inc., a biotechnology company, operates in the aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It also operates salmon farms using proprietary technology. In addition, the company offers AquAdvantage Salmon, a genetically engineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts. The company was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004. AquaBounty Technologies, Inc. was incorporated in 1991 and is headquartered in Harvard, Massachusetts.

Estrella Immunopharma NASDAQ:ESLA

$0.47 -0.01 (-1.47%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$0.47 +0.00 (+0.64%)

As of 10/2/2026 04:04 PM Eastern

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Marker Therapeutics NASDAQ:MRKR

$1.05 0.00 (0.00%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.08 +0.03 (+2.95%)

As of 10/2/2026 07:30 PM Eastern

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AQB, AKTX, ESLA, and MRKR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AQB, AKTX, ESLA, and MRKR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AQB, AKTX, ESLA, and MRKR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AQB, AKTX, ESLA, and MRKR Company Descriptions

Akari Therapeutics NASDAQ:AKTX

AquaBounty Technologies NASDAQ:AQB

Estrella Immunopharma NASDAQ:ESLA

Marker Therapeutics NASDAQ:MRKR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AQB, AKTX, ESLA, and MRKR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AQB, AKTX, ESLA, and MRKR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AQB, AKTX, ESLA, and MRKR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AQB, AKTX, ESLA, and MRKR Company Descriptions

Akari Therapeutics NASDAQ:AKTX

AquaBounty Technologies NASDAQ:AQB

Estrella Immunopharma NASDAQ:ESLA

Marker Therapeutics NASDAQ:MRKR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools